Skip to main content
AmigoFish

The Tirzepatide Boom Just Hit a Wall

From The Infographics Show · · 14 min

The player loads from YouTube only when you click. It uses YouTube's privacy-enhanced mode.

If the video does not play, the owner may have turned off embedding. Watch it on YouTube instead.

Watch on YouTube

Not rated yet

Description

Tirzepatide may be the most powerful weight-loss drug yet. Unlike semaglutide, which targets GLP-1, tirzepatide activates both GLP-1 and GIP, two hormones involved in hunger, insulin, and metabolism. That dual approach produced remarkable results.

In major clinical trials, patients lost more than 20% of their body weight, with some studies pushing average losses even higher. Tirzepatide also outperformed semaglutide head-to-head and showed benefits for sleep apnea, liver disease, blood pressure, and diabetes risk. But there are trade-offs. Some weight loss comes from lean muscle, the drug can cost hundreds or thousands of dollars per month, and weight often returns after treatment stops. High prices have also fueled a dangerous gray market where people buy raw tirzepatide powder online and mix injections themselves.

The drug works. Getting it safely is the harder part.

00:31 - Why Dieting Triggers the Body’s Survival System 01:29 - How Semaglutide Changed Weight Loss 02:33 - Why Tirzepatide Targets Two Hormones Instead of One 04:44 - How Mounjaro and Zepbound Became Blockbuster Drugs 05:17 - What Clinical Trials Reveal About Tirzepatide Weight Loss 06:55 - The Health Benefits Beyond the Scale 07:36 - Muscle Loss, Cost and the Problem of Weight Regain 10:08 - The Dangerous Black Market for Tirzepatide

Narrated by: Josh Risser

🔔 Don't forget to SUBSCRIBE! 🔔

SUGGEST A TOPIC: https://bit.ly/suggest-an-infographics-video

💬 Come chat with me: https://discord.gg/theinfoshow

🔖 MY SOCIAL PAGES TikTok ► https://www.tiktok.com/@theinfographicsshow Facebook ► https://www.facebook.com/TheInfographicsShow

📝 SOURCES: https://pastebin.com/0UeAtDsT

All videos are based on publicly available information unless otherwise noted.

Back to The Infographics Show · Report a problem